astrazeneca glp-1 Pays $185M to Add Oral Drug Candidate to Pipeline AstraZeneca's oral GLP-1 scored phase

Differential activity-dependent secretion of brain-derived neurotrophic factor from axon and dendrite

Developed by Korean dermatologists using cutting-edge research

Enzo Spisni, [email protected] These authors have contributed equally to this work $ These authors have contributed equally to this work and share last authorship ORCID: Fabio Vivarelli, orcid.org/0000-0002-8734-0985 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Hn na liu lng ny khng tht s cn thit vi hu ht mi ngi, n cng cha c chng minh l c th mang li li ch sc khe no vt tri hn cc liu dng khc